{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T08:13:33Z","timestamp":1778314413151,"version":"3.51.4"},"reference-count":46,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2022,1,21]],"date-time":"2022-01-21T00:00:00Z","timestamp":1642723200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/501100000245","name":"MSFHR","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000245","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,3,31]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Routine HIV drug resistance genotyping identified an integrase sequence harbouring T97A, E138K, G140S and Q148H, with high predicted resistance to all integrase strand transfer inhibitors (INSTIs).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To assess the impact of these substitutions alone and together on phenotypic INSTI susceptibility.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We constructed recombinant NL4.3 viruses harbouring all mutation combinations in the autologous integrase sequence. Viruses were grown in GFP-reporter CD4+ T-cells in the presence of 0.01\u20131000 nM raltegravir, elvitegravir, dolutegravir, bictegravir, and cabotegravir. Infection was measured by imaging cytometry.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Q148H-containing viruses lacking G140S failed to propagate or mutated in vitro, consistent with fitness costs. Statistically significant reductions in INSTI susceptibility were observed for several mutation combinations, as follows. T97A or G140S alone conferred 3.6- to 5.6-fold decreased susceptibility to raltegravir and elvitegravir. Two-mutation combinations conferred low-to-moderate resistance to raltegravir and elvitegravir only, except G140S\/Q148H which eliminated raltegravir and elvitegravir activity and conferred 24.6-, 7.9-, and 107.5-fold reduced susceptibility to dolutegravir, bictegravir and cabotegravir. Addition of E138K to G140S\/Q148H conferred 35.5, 11.6 and 208-fold reduced susceptibility to dolutegravir, bictegravir, and cabotegravir, while addition of T97A to G140S\/Q148H conferred 318, 121 and &amp;gt;1000-fold reduced susceptibility to these drugs. T97A\/E138K\/G140S\/Q148H in the autologous backbone conferred &amp;gt;300-fold reduced susceptibility to all INSTIs. Notably, bictegravir EC50 was significantly lower when T97A\/E138K\/G140S\/Q148H was introduced into NL4.3, suggesting that other mutations in the autologous sequence enhanced resistance.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>High-level dolutegravir, bictegravir and cabotegravir resistance requires multiple integrase substitutions including compensatory mutations. T97A and E138K further enhance the resistance conferred by G140S\/Q148H, yielding &amp;gt;300-fold decreased susceptibility to all INSTIs when all four mutations are present.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jac\/dkab498","type":"journal-article","created":{"date-parts":[[2021,12,24]],"date-time":"2021-12-24T20:09:49Z","timestamp":1640376589000},"page":"979-988","source":"Crossref","is-referenced-by-count":11,"title":["Impact of combinations of clinically observed HIV integrase mutations on phenotypic resistance to integrase strand transfer inhibitors (INSTIs): a molecular study"],"prefix":"10.1093","volume":"77","author":[{"given":"Peter K.","family":"Cheung","sequence":"first","affiliation":[{"name":"British Columbia Centre for Excellence in HIV\/AIDS, Vancouver, BC, Canada"},{"name":"Faculty of Health Sciences, Simon Fraser University, Burnaby, BC, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aniqa","family":"Shahid","sequence":"additional","affiliation":[{"name":"British Columbia Centre for Excellence in HIV\/AIDS, Vancouver, BC, Canada"},{"name":"Faculty of Health Sciences, Simon Fraser University, Burnaby, BC, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Winnie","family":"Dong","sequence":"additional","affiliation":[{"name":"British Columbia Centre for Excellence in HIV\/AIDS, Vancouver, BC, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katherine J.","family":"Lepik","sequence":"additional","affiliation":[{"name":"British Columbia Centre for Excellence in HIV\/AIDS, Vancouver, BC, Canada"},{"name":"Pharmacy Department, St. Paul\u2019s Hospital, Vancouver, BC, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julio S. G.","family":"Montaner","sequence":"additional","affiliation":[{"name":"British Columbia Centre for Excellence in HIV\/AIDS, Vancouver, BC, Canada"},{"name":"Division of Infectious Diseases, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark A.","family":"Brockman","sequence":"additional","affiliation":[{"name":"British Columbia Centre for Excellence in HIV\/AIDS, Vancouver, BC, Canada"},{"name":"Faculty of Health Sciences, Simon Fraser University, Burnaby, BC, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zabrina L.","family":"Brumme","sequence":"additional","affiliation":[{"name":"British Columbia Centre for Excellence in HIV\/AIDS, Vancouver, BC, Canada"},{"name":"Faculty of Health Sciences, Simon Fraser University, Burnaby, BC, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2722-5288","authenticated-orcid":false,"given":"Chanson J.","family":"Brumme","sequence":"additional","affiliation":[{"name":"British Columbia Centre for Excellence in HIV\/AIDS, Vancouver, BC, Canada"},{"name":"Division of Infectious Diseases, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2022,1,21]]},"reference":[{"key":"2022033111121576400_dkab498-B1","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1001\/jama.2018.8431","article-title":"Antiretroviral drugs for treatment and prevention of HIV Infection in adults: 2018 Recommendations of the International Antiviral Society-USA Panel","volume":"320","author":"Saag","year":"2018","journal-title":"JAMA"},{"key":"2022033111121576400_dkab498-B2","author":"European AIDS Clinical Society"},{"key":"2022033111121576400_dkab498-B3","article-title":"Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV","author":"Panel on Antiretroviral Guidelines for Adults and Adolescents"},{"key":"2022033111121576400_dkab498-B4","author":"World Health Organization","year":"2019"},{"key":"2022033111121576400_dkab498-B5","doi-asserted-by":"crossref","first-page":"3703","DOI":"10.3390\/v7072790","article-title":"Resistance against integrase strand transfer inhibitors and relevance to HIV persistence","volume":"7","author":"Mespl\u00e8de","year":"2015","journal-title":"Viruses"},{"key":"2022033111121576400_dkab498-B6","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofab297","article-title":"Case report: emergent resistance in a treatment-naive person with human immunodeficiency virus under bictegravir-based therapy","volume":"8","author":"Chamberlain","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"2022033111121576400_dkab498-B7","doi-asserted-by":"crossref","first-page":"104717","DOI":"10.1016\/j.antiviral.2020.104717","article-title":"Failure to bictegravir and development of resistance mutations in an antiretroviral-experienced patient","volume":"179","author":"Lozano","year":"2020","journal-title":"Antiviral Res"},{"key":"2022033111121576400_dkab498-B8","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1097\/QAD.0000000000001494","article-title":"Emergent drug resistance with integrase strand transfer inhibitor-based regimens","volume":"31","author":"Lepik","year":"2017","journal-title":"AIDS"},{"key":"2022033111121576400_dkab498-B9","doi-asserted-by":"crossref","DOI":"10.3390\/v12111330","article-title":"Emergence of resistance to integrase strand transfer inhibitors during dolutegravir containing triple-therapy in a treatment-experienced patient with pre-existing M184V\/I mutation","volume":"12","author":"Braun","year":"2020","journal-title":"Viruses"},{"key":"2022033111121576400_dkab498-B10","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1093\/jac\/dkab115","article-title":"Three-year study of pre-existing drug resistance substitutions and efficacy of bictegravir\/emtricitabine\/tenofovir alafenamide in HIV-1 treatment-naive participants","volume":"76","author":"Acosta","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"2022033111121576400_dkab498-B11","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1089\/aid.2020.0261","article-title":"Integrase strand transfer inhibitor resistance in integrase strand transfer inhibitor-naive persons","volume":"37","author":"Bailey","year":"2021","journal-title":"AIDS Res Hum Retroviruses"},{"key":"2022033111121576400_dkab498-B12","doi-asserted-by":"crossref","first-page":"ofaa202","DOI":"10.1093\/ofid\/ofaa202","article-title":"Emergent resistance to dolutegravir among INSTI-naive patients on first-line or second-line antiretroviral therapy: a review of published cases","volume":"7","author":"Cevik","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"2022033111121576400_dkab498-B13","doi-asserted-by":"crossref","first-page":"3135","DOI":"10.1093\/jac\/dkz256","article-title":"A systematic review of the genetic mechanisms of dolutegravir resistance","volume":"74","author":"Rhee","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2022033111121576400_dkab498-B14","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1093\/jac\/dkz417","article-title":"Integrase strand transfer inhibitor (INSTI)-resistance mutations for the surveillance of transmitted HIV-1 drug resistance","volume":"75","author":"Tzou","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"2022033111121576400_dkab498-B15","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s12977-018-0440-3","article-title":"Selective resistance profiles emerging in patient-derived clinical isolates with cabotegravir, bictegravir, dolutegravir, and elvitegravir","volume":"15","author":"Oliveira","year":"2018","journal-title":"Retrovirology"},{"key":"2022033111121576400_dkab498-B16","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1093\/infdis\/jiy428","article-title":"Accumulation of multiple mutations in vivo confers cross-resistance to new and existing integrase inhibitors","volume":"218","author":"Zhang","year":"2018","journal-title":"J Infect Dis"},{"key":"2022033111121576400_dkab498-B17","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofz060","article-title":"Prevalence of human immunodeficiency virus-1 integrase strand transfer inhibitor resistance in British Columbia, Canada between 2009 and 2016: a longitudinal analysis","volume":"6","author":"Kamelian","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"2022033111121576400_dkab498-B18","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.jviromet.2005.08.003","article-title":"Use of a novel GFP reporter cell line to examine replication capacity of CXCR4- and CCR5-tropic HIV-1 by flow cytometry","volume":"131","author":"Brockman","year":"2006","journal-title":"J Virol Methods"},{"key":"2022033111121576400_dkab498-B19"},{"key":"2022033111121576400_dkab498-B20","doi-asserted-by":"crossref","first-page":"694","DOI":"10.3390\/v12070694","article-title":"Multi-laboratory comparison of next-generation to Sanger-based sequencing for HIV-1 drug resistance genotyping","volume":"12","author":"Parkin","year":"2020","journal-title":"Viruses"},{"key":"2022033111121576400_dkab498-B21","doi-asserted-by":"crossref","first-page":"6913","DOI":"10.1128\/JVI.07133-11","article-title":"Uncommon pathways of immune escape attenuate HIV-1 integrase replication capacity","volume":"86","author":"Brockman","year":"2012","journal-title":"J Virol"},{"key":"2022033111121576400_dkab498-B22","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1021\/acs.jmedchem.5b01357","article-title":"A Parallel synthesis approach to the identification of novel diheteroarylamide-based compounds blocking HIV replication: potential inhibitors of HIV-1 pre-mRNA alternative splicing","volume":"59","author":"Cheung","year":"2016","journal-title":"J Med Chem"},{"key":"2022033111121576400_dkab498-B23","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1093\/nar\/gkn1050","article-title":"The G140S mutation in HIV integrases from raltegravir-resistant patients rescues catalytic defect due to the resistance Q148H mutation","volume":"37","author":"Delelis","year":"2009","journal-title":"Nucleic Acids Res"},{"key":"2022033111121576400_dkab498-B24","doi-asserted-by":"crossref","first-page":"e00014-19","DOI":"10.1128\/AAC.00014-19","article-title":"Comparison of the antiviral activity of bictegravir against HIV-1 and HIV-2 isolates and integrase inhibitor-resistant HIV-2 mutants","volume":"63","author":"Smith","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2022033111121576400_dkab498-B25","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/febs.15438","article-title":"Close-up: HIV\/SIV intasome structures shed new light on integrase inhibitor binding and viral escape mechanisms","volume":"288","author":"Engelman","year":"2021","journal-title":"FEBS J"},{"key":"2022033111121576400_dkab498-B26","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1093\/infdis\/jis750","article-title":"Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING Study","volume":"207","author":"Eron","year":"2013","journal-title":"J Infect Dis"},{"key":"2022033111121576400_dkab498-B27","doi-asserted-by":"crossref","first-page":"7086","DOI":"10.1128\/AAC.01474-16","article-title":"Antiviral Activity of Bictegravir (GS-9883), a Novel Potent HIV-1 Integrase Strand Transfer Inhibitor with an Improved Resistance Profile","volume":"60","author":"Tsiang","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2022033111121576400_dkab498-B28","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1093\/jac\/dkz021","article-title":"Resistance to integrase inhibitors: a national study in HIV-1-infected treatment-naive and -experienced patients","volume":"74","author":"Marcelin","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2022033111121576400_dkab498-B29","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1093\/jac\/dky198","article-title":"Prevalence and clinical impact of minority resistant variants in patients failing an integrase inhibitor-based regimen by ultra-deep sequencing","volume":"73","author":"Nguyen","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2022033111121576400_dkab498-B30","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofy221","article-title":"Rapid development of high-level resistance to dolutegravir with emergence of T97A mutation in 2 treatment-experienced individuals with baseline partial sensitivity to dolutegravir","volume":"5","author":"George","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"2022033111121576400_dkab498-B31","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1093\/jac\/dkaa471","article-title":"Progressive emergence of an S153F plus R263K combination of integrase mutations in the proviral DNA of one individual successfully treated with dolutegravir","volume":"76","author":"Pham","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"2022033111121576400_dkab498-B32","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1089\/aid.2016.0038","article-title":"Q148N, a novel integrase inhibitor resistance mutation associated with low-level reduction in elvitegravir susceptibility","volume":"32","author":"Varghese","year":"2016","journal-title":"AIDS Res Hum Retroviruses"},{"key":"2022033111121576400_dkab498-B33","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1093\/jac\/dkv333","article-title":"Deep analysis of HIV-1 natural variability across HIV-1 variants at residues associated with integrase inhibitor (INI) resistance in INI-naive individuals","volume":"71","author":"Ll\u00e1cer Delicado","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"2022033111121576400_dkab498-B34","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1473-3099(11)70249-3","article-title":"Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study","volume":"12","author":"Molina","year":"2012","journal-title":"Lancet Infect Dis"},{"key":"2022033111121576400_dkab498-B35","doi-asserted-by":"crossref","first-page":"e0172206","DOI":"10.1371\/journal.pone.0172206","article-title":"Lack of impact of pre-existing T97A HIV-1 integrase mutation on integrase strand transfer inhibitor resistance and treatment outcome","volume":"12","author":"Abram","year":"2017","journal-title":"PLoS One"},{"key":"2022033111121576400_dkab498-B36","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.antiviral.2015.04.014","article-title":"Natural polymorphism S119R of HIV-1 integrase enhances primary INSTI resistance","volume":"119","author":"Hachiya","year":"2015","journal-title":"Antiviral Res"},{"key":"2022033111121576400_dkab498-B37","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1128\/AAC.42.2.269","article-title":"A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs","volume":"42","author":"Hertogs","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"2022033111121576400_dkab498-B38","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1128\/AAC.44.4.920-928.2000","article-title":"A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1","volume":"44","author":"Petropoulos","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"2022033111121576400_dkab498-B39","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1097\/01.qai.0000159517.78100.7b","article-title":"Nonnucleoside reverse transcriptase inhibitor phenotypic hypersusceptibility can be demonstrated in different assays","volume":"39","author":"Shulman","year":"2005","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2022033111121576400_dkab498-B40","doi-asserted-by":"crossref","first-page":"e02557-19","DOI":"10.1128\/AAC.02557-19","article-title":"Antiviral activity of tenofovir alafenamide against HIV-1 with thymidine analog-associated mutations and M184V","volume":"64","author":"Margot","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2022033111121576400_dkab498-B41","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1128\/AAC.02568-12","article-title":"Impact of primary elvitegravir resistance-associated mutations in HIV-1 integrase on drug susceptibility and viral replication fitness","volume":"57","author":"Abram","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"2022033111121576400_dkab498-B42","doi-asserted-by":"crossref","first-page":"e22206","DOI":"10.1002\/jcla.22206","article-title":"Agreement between an in-house replication competent and a reference replication defective recombinant virus assay for measuring phenotypic resistance to HIV-1 protease, reverse transcriptase, and integrase inhibitors","volume":"32","author":"Saladini","year":"2018","journal-title":"J Clin Lab Anal"},{"key":"2022033111121576400_dkab498-B43","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jviromet.2016.10.002","article-title":"Development of a phenotypic susceptibility assay for HIV-1 integrase inhibitors","volume":"238","author":"Heger","year":"2016","journal-title":"J Virol Methods"},{"key":"2022033111121576400_dkab498-B44","doi-asserted-by":"crossref","first-page":"9495","DOI":"10.1128\/JVI.01107-16","article-title":"Novel acylguanidine-based inhibitor of HIV-1","volume":"90","author":"Mwimanzi","year":"2016","journal-title":"J Virol"},{"key":"2022033111121576400_dkab498-B45","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.antiviral.2018.02.017","article-title":"Inhibition of NF-\u03baB-dependent HIV-1 replication by the marine natural product bengamide A","volume":"152","author":"Tietjen","year":"2018","journal-title":"Antiviral Res"},{"key":"2022033111121576400_dkab498-B46","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1021\/acsmedchemlett.1c00428","article-title":"2-Trifluoromethylthiazole-5-carboxamides: analogues of a stilbene-based anti-HIV agent that impact HIV mRNA processing","volume":"12","author":"Zamiri","year":"2021","journal-title":"ACS Med Chem Lett"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/77\/4\/979\/43192475\/dkab498.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/77\/4\/979\/43192475\/dkab498.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T13:41:25Z","timestamp":1648734085000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/77\/4\/979\/6513314"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,21]]},"references-count":46,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,1,21]]},"published-print":{"date-parts":[[2022,3,31]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkab498","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,4,1]]},"published":{"date-parts":[[2022,1,21]]}}}